These innovative molecules represent a significant progression in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose levels. https://tamzinbubz916554.arwebo.com/61436201/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide